Trials / Completed
CompletedNCT00151710
Effects of Pioglitazone in Congenital Adrenal Hyperplasia
Effects of Pioglitazone in Glucocorticoid-Induced Insulin Resistance. Studies in Congenital Adrenal Hyperplasia.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Radboud University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Congenital adrenal hyperplasia, an autosomal recessive condition, is mainly caused by mutations in the gene 21-hydroxylase and is treated with glucocorticoids in a slightly supraphysiological dose. Adult patients seem to be characterized by insulin resistance, which may be caused by the glucocorticoids and/or the accompanying obesity. The hypothesis of this study is that pioglitazone can improve insulin sensitivity and correlated cardiovascular risk factors in this specific group of patients. This will be tested in a randomized, placebo-controlled, cross-over trial; insulin sensitivity will be quantified by euglycemic hyperinsulinemic clamp studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pioglitazone |
Timeline
- First posted
- 2005-09-09
- Last updated
- 2007-03-01
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00151710. Inclusion in this directory is not an endorsement.